MAM
Patanjali launches Coronil drug for Covid2019
MUMBAI: Baba Ramdev's Patanjali launched an ayurvedic medicine for treating Covid2019 today at Patanjali Yogpeeth in Haridwar.
Earlier this month, Patanjali Ayurved managing director Acharya Balkrishna had claimed that an ayurvedic medicine developed by the company has been able to cure Covid2019 patients within five to 14 days. Patanjali Ayurved Ltd MD Acharya Balkrishna had announced the launch on Twitter on Monday evening.
"We've prepared the first ayurvedic clinically-controlled, research, evidence and trial based medicine for Covid2019. We conducted a clinical case study and clinical controlled trial and found 69 per cent patients recovered in three days and 100 per cent patients recovered in seven days," said Ramdev.
Ramdev claims that there has been 0 per cent death rate and 100 per cent recovery rate has been observed, around 69 per cent of the people recovered within six days. 100 per cent of the people has recovered thanks to the medicine made by it.
He also stated that they have done every research.
"We appointed a team of scientists after Covid2019 outbreak. Firstly, the simulation was done and compounds were identified which can fight the virus and stop its spread in the body. Then, we conducted a clinical case study on hundreds of positive patients and we have got 100 per cent favourable results," Balkrishna said at the launch.
"After taking our medicine, patients recovered in five to 14 days and then tested negative. So, we can say the cure for Covid2019 is possible through Ayurveda. We are performing controlled clinical trials only. In the next four to five days, evidence and data will be released by us," he added.
The medicine has been manufactured by Haridwar’s Divya Pharmacy and Patanjali Ayurved Ltd in Haridwar, based on a joint research by Patanjali Research Institute in Haridwar and the National Institute of Medical Science, Jaipur.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
